OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Glenmark Pharmaceuticals has partnered with SaNOtize to manufacture, market, and distribute NONS to India, Singapore, Malaysia, Hong Kong, and more.
SaNOtize and Glenmark Pharmaceuticals announced on August 2, 2021 an exclusive long-term strategic partnership to manufacture, market, and distribute SaNOtize’s nitric oxide nasal spray (NONS) for COVID-19 treatment to India and other Asian markets, including Singapore, Malaysia Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste, and Vietnam.
NONS were found to be a safe and effective antiviral treatment to prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms in SaNOtize’s March 2021 clinical trials.
NONS is designed to kill the COVID-19 virus in the upper airways, preventing it from incubating and spreading to the lungs. It is based on nitric oxide, which has proven anti-microbial properties and a direct effect on SARS-CoV-2.
The Subject Expert Committee of India’s Central Drugs Standard Control Organisation recommended a Phase III clinical trial for NONS to be conducted in Indian patients in the coming weeks. The Phase III trial is expected to be completed by Q4 2021, followed by a commercial launch.
Source: Businesswire, Glenmark Pharmaceuticals, SaNOtize